Tirzepatide treatment for 12 months resolves severe OSA in obese patient, improving airway physiology

Obstructive sleep apnea (OSA) is a prevalent sleep disorder strongly linked to obesity, characterized by recurrent upper airway collapse during sleep. Current treatments often involve continuous positive airway pressure (CPAP) or surgical interventions, which can have compliance issues or significant risks. Weight loss is a primary recommendation, but often difficult to achieve and sustain. Glucagon-like peptide-1 receptor (GLP-1R) agonists, like tirzepatide (a dual GLP-1/GIP agonist), have shown significant efficacy in weight reduction and are increasingly being explored for their potential direct effects on OSA pathophysiology beyond just weight loss, targeting underlying mechanisms like airway patency and ventilatory control.

This case report details a 35-year-old obese man with severe OSA who received tirzepatide treatment for 12 months as part of the SURMOUNT-OSA trial. The patient's body-mass index (BMI) and apnea-hypopnea index (AHI) were monitored over this period. Researchers also assessed changes in endotypic traits related to OSA, including upper-airway patency, compensatory pharyngeal muscle responsiveness, loop gain, and arousal threshold to understand the mechanistic shifts beyond simple weight reduction. No specific dose or route was mentioned in the abstract, but the duration was clearly stated.

After 12 months of tirzepatide treatment, the patient demonstrated significant improvements across multiple metrics. His body-mass index (BMI) decreased substantially from 31.0 to 24.9 kg/m², indicating a 20% reduction. Concurrently, the apnea-hypopnea index (AHI), a primary measure of OSA severity, plummeted from 54.8 to 4.4 events/h, effectively resolving his severe OSA. This represents a 92% reduction in AHI. Beyond weight loss, the study observed favorable shifts in endotypic traits contributing to OSA improvement. These included enhanced upper-airway patency, increased compensatory pharyngeal muscle responsiveness, and a notable reduction in loop gain, which reflects improved ventilatory control stability. A lower arousal threshold was also noted, although paradoxically, event duration was observed to be longer. These findings suggest a multifaceted improvement in OSA pathophysiology.

The patient's AHI decreased from 54.8 to 4.4 events/h, marking a 92% improvement and resolution of severe OSA.